Coal Tar
Active ingredient
Sold as RevitaDERM PSORIASIS · Medicasp Anti-Dandruff · DERM OIL · ODANS LIQUOR CARBONIS…
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Topical
- Markets covered
- 3
- Products on record
- 10
- FDA reports (12 mo)
- 71
Overview
Plain-language summary, compiled from the cited regulatory records
Coal Tar is an active ingredient used in topical treatments [1]. It is approved to control symptoms associated with dandruff, seborrheic dermatitis, and psoriasis [1].
This ingredient is available under various brand names, including RevitaDERM PSORIASIS and Medicasp Anti-Dandruff [1]. In the last 12 months, there have been 71 adverse event reports associated with products containing coal tar [2]. The most frequently reported adverse events include vomiting, rheumatoid arthritis, sinusitis, rhinorrhea, and sensory loss [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 4 | December 4, 2025 |
| GB United Kingdom | MHRA | 2 | February 17, 2025 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
USUnited States· FDA
4 products
Uses
Use controls the symptom of: dandruff seborrheic dermatitis psoriasis
How to take
GBUnited Kingdom· MHRA
2 products
Uses
For the topical treatment of psoriasis of the scalp.
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (2)
Drug interactions
Known interactions involving Coal Tar. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0464b4ff-1be1-4d… · revised May 9, 2024 [PDF]
- [2]MHRA (UK) · PL001735001 · revised February 17, 2025
- [3]Health Canada (DPD) · 02439085 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.